Case reports in ophthalmology · 2026
Anterior Chamber Migration of Dexamethasone Implant in a Patient Implanted with Carlevale Sutureless Scleral Fixation Intraocular Lens: A Case Report.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sejournet Lucas, Bontemps Justine, Mathis Thibaud, Kodjikian Laurent
Аннотация
INTRODUCTION: To report a case of anterior chamber migration of the dexamethasone intravitreal implant (DEX-I) through a new type of scleral fixated lens, the Carlevale® intraocular lens (IOL) (Cutting Edge, Italy).
CASE PRESENTATION: A 74-year-old pseudophakic man with a history of macular edema (ME) secondary to retinal vein occlusion had been receiving DEX-I injections every 4 months for 10 years. During follow-up, he spontaneously presented an IOL luxation into the vitreous cavity, treated surgically with explantation and Carlevale® IOL implantation. One month after this surgery, an injection of DEX-I was performed, due to recurrence of the ME. Seven days after, the patient presented DEX-I migration into the anterior chamber along with corneal edema, requiring implant removal. After aspiration through a 20-gauge catheter connected to a syringe corneal edema decreased in 7 days allowing an improvement in visual acuity.
CONCLUSION: Migration of the DEX-I into the anterior chamber remains a potential complication in vitrectomized eyes with capsular defects, even with the use of scleral-fixated IOLs such as the Carlevale®, which features a large optic. This highlights the importance of careful patient selection and postoperative monitoring in such cases.
CASE PRESENTATION: A 74-year-old pseudophakic man with a history of macular edema (ME) secondary to retinal vein occlusion had been receiving DEX-I injections every 4 months for 10 years. During follow-up, he spontaneously presented an IOL luxation into the vitreous cavity, treated surgically with explantation and Carlevale® IOL implantation. One month after this surgery, an injection of DEX-I was performed, due to recurrence of the ME. Seven days after, the patient presented DEX-I migration into the anterior chamber along with corneal edema, requiring implant removal. After aspiration through a 20-gauge catheter connected to a syringe corneal edema decreased in 7 days allowing an improvement in visual acuity.
CONCLUSION: Migration of the DEX-I into the anterior chamber remains a potential complication in vitrectomized eyes with capsular defects, even with the use of scleral-fixated IOLs such as the Carlevale®, which features a large optic. This highlights the importance of careful patient selection and postoperative monitoring in such cases.